Literature DB >> 9756744

Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained In vitro.

S Dessus-Babus1, C M Bébéar, A Charron, C Bébéar, B de Barbeyrac.   

Abstract

The L2 reference strain of Chlamydia trachomatis was exposed to subinhibitory concentrations of ofloxacin (0.5 microg/ml) and sparfloxacin (0.015 microg/ml) to select fluoroquinolone-resistant mutants. In this study, two resistant strains were isolated after four rounds of selection. The C. trachomatis mutants presented with high-level resistance to various fluoroquinolones, particularly to sparfloxacin, for which a 1,000-fold increase in the MICs for the mutant strains compared to the MIC for the susceptible strain was found. The MICs of unrelated antibiotics (doxycycline and erythromycin) for the mutant strains were identical to those for the reference strain. The gyrase (gyrA, gyrB) and topoisomerase IV (parC, parE) genes of the susceptible and resistant strains of C. trachomatis were partially sequenced. A point mutation was found in the gyrA quinolone-resistance-determining region (QRDR) of both resistant strains, leading to a Ser83-->Ile substitution (Escherichia coli numbering) in the corresponding protein. The gyrB, parC, and parE QRDRs of the resistant strains were identical to those of the reference strain. These results suggest that in C. trachomatis, DNA gyrase is the primary target of ofloxacin and sparfloxacin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9756744      PMCID: PMC105861     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  52 in total

1.  New topoisomerase essential for chromosome segregation in E. coli.

Authors:  J Kato; Y Nishimura; R Imamura; H Niki; S Hiraga; H Suzuki
Journal:  Cell       Date:  1990-10-19       Impact factor: 41.582

Review 2.  Treatment of chlamydial genital infection.

Authors:  G L Ridgway
Journal:  J Antimicrob Chemother       Date:  1997-09       Impact factor: 5.790

3.  Cloning and sequencing of the Escherichia coli gyrA gene coding for the A subunit of DNA gyrase.

Authors:  S L Swanberg; J C Wang
Journal:  J Mol Biol       Date:  1987-10-20       Impact factor: 5.469

4.  Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.

Authors:  L M Fisher; J M Lawrence; I C Josty; R Hopewell; E E Margerrison; M E Cullen
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

5.  Structure and function of the region of the replication origin of the Bacillus subtilis chromosome. III. Nucleotide sequence of some 10,000 base pairs in the origin region.

Authors:  S Moriya; N Ogasawara; H Yoshikawa
Journal:  Nucleic Acids Res       Date:  1985-04-11       Impact factor: 16.971

6.  Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi.

Authors:  C M Fraser; S Casjens; W M Huang; G G Sutton; R Clayton; R Lathigra; O White; K A Ketchum; R Dodson; E K Hickey; M Gwinn; B Dougherty; J F Tomb; R D Fleischmann; D Richardson; J Peterson; A R Kerlavage; J Quackenbush; S Salzberg; M Hanson; R van Vugt; N Palmer; M D Adams; J Gocayne; J Weidman; T Utterback; L Watthey; L McDonald; P Artiach; C Bowman; S Garland; C Fuji; M D Cotton; K Horst; K Roberts; B Hatch; H O Smith; J C Venter
Journal:  Nature       Date:  1997-12-11       Impact factor: 49.962

7.  DNA cloning and organization of the Staphylococcus aureus gyrA and gyrB genes: close homology among gyrase proteins and implications for 4-quinolone action and resistance.

Authors:  R Hopewell; M Oram; R Briesewitz; L M Fisher
Journal:  J Bacteriol       Date:  1990-06       Impact factor: 3.490

8.  Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli.

Authors:  H Yoshida; M Bogaki; M Nakamura; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

9.  Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones.

Authors:  M E Cullen; A W Wyke; R Kuroda; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

10.  Relative resistance to erythromycin in Chlamydia trachomatis.

Authors:  A Mourad; R L Sweet; N Sugg; J Schachter
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

View more
  27 in total

1.  Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.

Authors:  M R Hammerschlag; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 2.  Quinolones in sexually transmitted diseases: state of the art.

Authors:  G L Ridgway
Journal:  Drugs       Date:  1999       Impact factor: 9.546

3.  Antibiotic susceptibilities of Parachlamydia acanthamoeba in amoebae.

Authors:  M Maurin; A Bryskier; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

4.  Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae.

Authors:  Paul F Riska; Andrei Kutlin; Patrick Ajiboye; Arnold Cua; Patricia M Roblin; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 5.  Chlamydial persistence: beyond the biphasic paradigm.

Authors:  Richard J Hogan; Sarah A Mathews; Sanghamitra Mukhopadhyay; James T Summersgill; Peter Timms
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

Review 6.  Antibiotic resistance in Chlamydiae.

Authors:  Kelsi M Sandoz; Daniel D Rockey
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

7.  Resistance to a novel antichlamydial compound is mediated through mutations in Chlamydia trachomatis secY.

Authors:  Kelsi M Sandoz; Steven G Eriksen; Brendan M Jeffrey; Robert J Suchland; Timothy E Putman; Dennis E Hruby; Robert Jordan; Daniel D Rockey
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

8.  Serine-to-asparagine substitution in the GyrA gene leads to quinolone resistance in moxifloxacin-exposed Chlamydia pneumoniae.

Authors:  Jan Rupp; Andreas Gebert; Werner Solbach; Matthias Maass
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 9.  The case for further treatment studies of uncomplicated genital Chlamydia trachomatis infection.

Authors:  P Horner
Journal:  Sex Transm Infect       Date:  2006-08       Impact factor: 3.519

Review 10.  Concurrent gonococcal and chlamydial infection: how best to treat.

Authors:  A J Robinson; G L Ridgway
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.